Hone Bio Limited 11076788 false 2024-08-01 2025-07-31 2025-07-31 The principal activity of the company is the research and experimental development of cellular therapy technologies. Digita Accounts Production Advanced 6.30.9574.0 true true 11076788 2024-08-01 2025-07-31 11076788 2025-07-31 11076788 bus:OrdinaryShareClass1 2025-07-31 11076788 bus:OrdinaryShareClass2 2025-07-31 11076788 bus:OrdinaryShareClass3 2025-07-31 11076788 core:WithinOneYear 2025-07-31 11076788 core:FurnitureFittingsToolsEquipment 2025-07-31 11076788 core:OtherPropertyPlantEquipment 2025-07-31 11076788 core:Share-basedArrangement1 2025-07-31 11076788 core:Share-basedArrangement2 2025-07-31 11076788 bus:SmallEntities 2024-08-01 2025-07-31 11076788 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 11076788 bus:FilletedAccounts 2024-08-01 2025-07-31 11076788 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 11076788 bus:RegisteredOffice 2024-08-01 2025-07-31 11076788 bus:Director1 2024-08-01 2025-07-31 11076788 bus:Director10 2024-08-01 2025-07-31 11076788 bus:Director12 2024-08-01 2025-07-31 11076788 bus:Director13 2024-08-01 2025-07-31 11076788 bus:Director5 2024-08-01 2025-07-31 11076788 bus:Director6 2024-08-01 2025-07-31 11076788 bus:OrdinaryShareClass1 2024-08-01 2025-07-31 11076788 bus:OrdinaryShareClass2 2024-08-01 2025-07-31 11076788 bus:OrdinaryShareClass3 2024-08-01 2025-07-31 11076788 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 11076788 core:FurnitureFittingsToolsEquipment 2024-08-01 2025-07-31 11076788 core:OfficeEquipment 2024-08-01 2025-07-31 11076788 core:OtherPropertyPlantEquipment 2024-08-01 2025-07-31 11076788 core:PlantMachinery 2024-08-01 2025-07-31 11076788 core:Share-basedArrangement1 2024-08-01 2025-07-31 11076788 core:Share-basedArrangement2 2024-08-01 2025-07-31 11076788 countries:EnglandWales 2024-08-01 2025-07-31 11076788 2024-07-31 11076788 core:FurnitureFittingsToolsEquipment 2024-07-31 11076788 core:OtherPropertyPlantEquipment 2024-07-31 11076788 core:Share-basedArrangement1 2024-07-31 11076788 core:Share-basedArrangement2 2024-07-31 11076788 2023-08-01 2024-07-31 11076788 2024-07-31 11076788 bus:OrdinaryShareClass1 2024-07-31 11076788 bus:OrdinaryShareClass2 2024-07-31 11076788 bus:OrdinaryShareClass3 2024-07-31 11076788 core:WithinOneYear 2024-07-31 11076788 core:FurnitureFittingsToolsEquipment 2024-07-31 11076788 core:OtherPropertyPlantEquipment 2024-07-31 11076788 core:Share-basedArrangement1 2024-07-31 11076788 core:Share-basedArrangement2 2024-07-31 11076788 core:Share-basedArrangement1 2023-08-01 2024-07-31 11076788 core:Share-basedArrangement2 2023-08-01 2024-07-31 11076788 core:Share-basedArrangement1 2023-07-31 11076788 core:Share-basedArrangement2 2023-07-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 11076788

Hone Bio Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 July 2025

Pages for filing with Registrar

 

Hone Bio Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Hone Bio Limited

Company Information

Directors

Dr A W Perriman

Dr B M Carter

Dr A M Chapman

Dr H S Destecroix

Dr M M T Khan

Mr K MacDonald

Registered office

Science Creates Old Market
Midland Road
Bristol
BS2 0JZ

Registered number

11076788

Accountant

Corrigan Accountants Limited
1st Floor
25 King Street
Bristol
BS1 4PB

 

Hone Bio Limited

(Registration number: 11076788)
Balance Sheet as at 31 July 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

111,178

107,152

Current assets

 

Debtors

5

163,361

104,646

Cash at bank and in hand

 

285,969

227,676

 

449,330

332,322

Creditors: Amounts falling due within one year

6

(49,009)

(67,891)

Net current assets

 

400,321

264,431

Net assets

 

511,499

371,583

Capital and reserves

 

Called up share capital

7

6,101

5,628

Share premium reserve

5,727,142

5,477,723

Share options reserve

8,319

4,780

Profit and loss account

(5,230,063)

(5,116,548)

Total equity

 

511,499

371,583

 

Hone Bio Limited

(Registration number: 11076788)
Balance Sheet as at 31 July 2025

For the financial year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised for issue by the Board on 31 July 2026 and signed on its behalf by:
 

.........................................

Dr B M Carter
Director

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

1

Statutory information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Science Creates Old Market
Midland Road
Bristol
BS2 0JZ

2

Accounting policies

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in pounds sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Going concern

The financial statements have been prepared on a going concern basis. The company incurred a loss after taxation in the year and the balance sheet reports net assets of £511,499 at the year-end (2024: £371,583 net assets).

In assessing the appropriateness of this basis, the directors have assessed the company's ability to continue as a going concern for a period of at least twelve months from the date of approval of these financial statements. The directors acknowledge that the company will require additional funding in order to meet its liabilities as they fall due and continue its planned activities.

The directors are currently engaged in an investment fundraising process and expect a further investment round to complete during the third quarter of 2026. In the period since the year end, the company's activities have been supported through a combination of contract income generated from short-term commercial projects and funding provided by the directors.

At the date of approval of these financial statements, the proposed investment has not yet been contractually committed.

Accordingly, a material uncertainty exists on the company's ability to continue as a going concern. However, the directors remain confident that the planned investment round will be successfully completed and that sufficient funding will be available to enable the company to meet its obligations as they fall due for the foreseeable future. Accordingly, the directors continue to adopt the going concern basis of accounting in preparing the annual financial statements.

Government grants

Government grants are recognised, using the performance model, at the fair value of the asset received or receivable when there is reasonable assurance that the company will comply with conditions attaching to them and the grants will be received.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible fixed assets

Tangible fixed assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible fixed assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Office equipment

4 years straight line

Plant and machinery

4 years straight line

Research and development costs

Research and development costs are written off to profit or loss in the year incurred.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade creditors

Trade creditors are recognised at the transaction price.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employees' services are received.

Share based payments

The company has issued options over its unissued shares to certain employees. The cost of equity-settled transactions is measured by reference to the fair value of the equity instruments granted at the date at which they are granted and is recognised as an expense over the vesting period, which ends on the date on which the option holder becomes fully entitled to the award. Fair value is determined using the Black Scholes pricing model.

At each balance sheet date before vesting, the cumulative expense is calculated, representing the extent to which the vesting period has expired and management’s best estimate of the achievement or otherwise of non-market conditions and of the number of equity instruments that will ultimately vest. The movement in cumulative expense since the previous balance sheet date is recognised in the profit and loss account, with a corresponding entry in equity.

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 7 (2024 - 6).

4

Tangible fixed assets

Office Equipment
 £

Plant and Machinery
£

Total
£

Cost

At 1 August 2024

6,201

411,613

417,814

Additions

-

72,681

72,681

At 31 July 2025

6,201

484,294

490,495

Depreciation

At 1 August 2024

4,036

306,626

310,662

Charge for the year

1,047

67,608

68,655

At 31 July 2025

5,083

374,234

379,317

Carrying amount

At 31 July 2025

1,118

110,060

111,178

At 31 July 2024

4,310

102,842

107,152

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

5

Debtors: amounts falling due within one year

2025
£

2024
£

Other debtors

6,783

6,060

VAT

32,389

30,107

Prepayments and accrued income

124,189

68,479

163,361

104,646

6

Creditors

2025
£

2024
£

Trade creditors

20,693

18,803

Taxation and social security

4,917

14,833

Other creditors

14,723

20,059

Accruals and deferred income

8,676

14,196

49,009

67,891

7

Share capital

Allotted, called up and fully paid shares

 

2025

2024

 

No.

£

No.

£

Ordinary shares of £0.01 each

175,170

1,751.70

175,170

1,751.70

B Ordinary shares of £0.01 each

325,400

3,254.00

325,400

3,254.00

B-1 Ordinary shares of £0.01 each

109,558

1,095.58

62,194

621.94

 

610,128

6,101

562,764

5,628

In November 2024, 47,364 B-1 Ordinary shares with an aggregate nominal value of £473.64 were issued for an aggregate consideration of £249,892.
 

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

8

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2025
£

2024
£

16,140

15,351

9

Share-based payments

EMI Share option scheme

Scheme details and movements

Share options were granted to certain employees under an EMI share option scheme. The options are exercisable provided criteria are met regarding continued employment and achievement of certain targets.

The options expire ten years after the grant date.

The movements in the number of share options during the year were as follows:

2025
Number

2024
Number

Outstanding, start of period

619

3,115

Granted during the period

-

37

Forfeited during the period

-

(2,533)

Outstanding, end of period

619

619

Exercisable, end of period

619

619

 

Hone Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

The movements in the weighted average exercise price of share options during the year were as follows:

2025
£

2024
£

Outstanding, start of period

72.05

64.50

Granted during the period

-

72.05

Forfeited during the period

-

(67.68)

Outstanding, end of period

72.05

72.05

Exercisable, end of period

72.05

72.05

Unapproved Share option scheme

Scheme details and movements

Share options were granted to certain employees under an unapproved share option scheme. The options are exercisable provided criteria are met regarding continued employment and achievement of certain targets.

The options expire ten years after the grant date.

The movements in the number of share options during the year were as follows:

2025
Number

2024
Number

Outstanding, start of period

222

402

Forfeited during the period

-

(180)

Outstanding, end of period

222

222

Exercisable, end of period

222

222

The movements in the weighted average exercise price of share options during the year were as follows:

2025
£

2024
£

Outstanding, start of period

117.92

104.55

Forfeited during the period

-

(88.06)

Outstanding, end of period

117.92

117.92

Exercisable, end of period

117.92

117.92